Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity.
Asmis
Timothy R
TR
Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology, 1275 York Avenue, Howard 910, New York, NY 10065, USA.
Chung
Ki Y
KY
Teitcher
Jerrold B
JB
Kelsen
David P
DP
Shah
Manish A
MA
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology; D011006:Pneumatosis Cystoides Intestinalis / Q000139:chemically induced* / Q000175:diagnosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab